In regard to cholestasis, elafibranor activates PPARα which inhibits CYP7A1 expression leading to a reduction in BAs synthesis, whereas the induction of CYP3A4, SULT2A1 and UGT2B4, and the expression of BSEP and MRP2, decrease BAs output and toxicity [68]. This evidence concerns the gene PPARA and cholestasis.